Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerótica
AA Pavía-López, MA Alcocer-Gamba… - … de cardiología de …, 2022 - scielo.org.mx
Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y
enfermedad cardiovascular aterosclerótica SciELO - Scientific Electronic Library Online vol.92 …
enfermedad cardiovascular aterosclerótica SciELO - Scientific Electronic Library Online vol.92 …
[HTML][HTML] Disorders of lipid metabolism. Clinical Guidelines 2023
MV Ezhov, VV Kukharchuk… - Russian Journal of …, 2023 - russjcardiol.elpub.ru
Disorders of lipid metabolism. Clinical Guidelines 2023 | Ezhov | Russian Journal of
Cardiology Russian Journal of Cardiology eng | рус User ISSN 1560-4071 (Print) ISSN …
Cardiology Russian Journal of Cardiology eng | рус User ISSN 1560-4071 (Print) ISSN …
[HTML][HTML] Нарушения липидного обмена. Клинические рекомендации 2023
МВ Ежов, ВВ Кухарчук, ИВ Сергиенко… - Российский …, 2023 - cyberleninka.ru
При участии: Национального общества по изучению атеросклероза (НОА), Российской
ассоциации эндокринологов (РАЭ), Российского общества кардиосоматической …
ассоциации эндокринологов (РАЭ), Российского общества кардиосоматической …
The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low‐Density Lipoprotein Levels: A Systematic Review and …
T Jamialahmadi, F Baratzadeh, Ž Reiner… - Mediators of …, 2021 - Wiley Online Library
Background. Elevated plasma low‐density lipoprotein cholesterol (LDL‐C) is the main risk
factor for atherosclerotic cardiovascular disease (ASCVD). Statins are the drugs of choice for …
factor for atherosclerotic cardiovascular disease (ASCVD). Statins are the drugs of choice for …
[HTML][HTML] 2023: The year in cardiovascular disease–the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
In 2023 there are still even 75% of patients over the target of low-density lipoprotein
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab
U Landmesser, J McGinniss, PG Steg… - European Journal of …, 2022 - academic.oup.com
Aims European guidelines set low-density lipoprotein cholesterol (LDL-C) treatment goals<
1.4 mmol/L after acute coronary syndrome (ACS), and< 1.0 mmol/L for patients with …
1.4 mmol/L after acute coronary syndrome (ACS), and< 1.0 mmol/L for patients with …
Lipoprotein (a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
E Woźniak, M Broncel, A Woźniak, J Satała… - Scientific Reports, 2024 - nature.com
Heterozygous familial hypercholesterolemia (HeFH) is a common autosomal-dominant
inherited disorder associated with atherosclerotic cardiovascular disease (ASCVD). HeFH …
inherited disorder associated with atherosclerotic cardiovascular disease (ASCVD). HeFH …
[HTML][HTML] Российские клинические рекомендации по нарушению липидного обмена 2024 г. Что нового?
ИВ Сергиенко - РМЖ, 2023 - cyberleninka.ru
Нарушения липидного обмена, или дислипидемии, включают целый спектр состояний,
когда концентрации липидов и липопротеинов крови выходят за пределы нормы …
когда концентрации липидов и липопротеинов крови выходят за пределы нормы …
[HTML][HTML] Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
J Lee, SH Lee - The Korean Journal of Internal Medicine, 2023 - ncbi.nlm.nih.gov
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD),
and statins are the primary therapeutic options for reducing low-density lipoprotein …
and statins are the primary therapeutic options for reducing low-density lipoprotein …
[HTML][HTML] The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
D Kounatidis, N Tentolouris, NG Vallianou, I Mourouzis… - Metabolites, 2024 - mdpi.com
Atherosclerotic cardiovascular disease poses a significant global health issue, with
dyslipidemia standing out as a major risk factor. In recent decades, lipid-lowering therapies …
dyslipidemia standing out as a major risk factor. In recent decades, lipid-lowering therapies …